FDA is Removing the “Black Box” Warnings of Breast Cancer from Menopausal Hormone Therapy Products

FDA-OncoDaily

Can Germany Secure Its Pills Without China?

germany

MEP Tilly Metz on Political Courage and Europe’s Cancer Policy – CancerWorld

CancerWorld

Abstract Submission is Open for ASCO 2026 Annual Meeting

ASCO 2026

100 Influential People in Oncology 2025 - Nominations are Open!

100 Influential People in Oncology 2025

Angela Mastronuzzi: Meta-Analysis Reveals Key Findings in Infant-Type Hemispheric Glioma

Angela Mastronuzzi

Liang Cheng: The Role of Liquid Biopsy in Genitourinary Malignancies

Liang Cheng

Andreas Charalambous will Chair the 2027–2028 MASCC/ISOO Annual Meetings

Andreas Charalambous

OncoCalendar

« All Events

  • This event has passed.

Overview and clarification of the current HR+ HER2- EBC treatment landscape by SPCC

Nov 27, 2024 • 6:00 PM - 7:30 PM
Overview and clarification of the current HR+ HER2- EBC treatment landscape by SPCC

Overview and clarification of the current HR+ HER2- EBC treatment landscape by SPCC will be held at November 27, 2024.

It is a live webinar by SPCC and the event will feature presentations on the latest advancements in breast cancer treatment, with an introduction by Fiorita Poulakaki from Greece. Michael Gnant from Austria will discuss the de-escalation and escalation of surgery, radiotherapy, and adjuvant treatments. Stephen Johnston from the UK will focus on personalizing adjuvant endocrine therapy, exploring current perspectives and future directions. Following the talks, there will be a 10-minute discussion and Q&A session, allowing participants to engage with the speakers.

The event will conclude with closing remarks by Fiorita Poulakaki, summarizing the key takeaways.

Details

Organizer